Access cutting-edge liver cancer treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.
Access liver cancer specialists in Portland at no cost
This study follows strict safety protocols and ethical guidelines
All study-related liver cancer treatment provided free
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents. The study includes a dose escalation phase (Part 1 or Phase I) to determine the Recommended Phase II Dose (RP2D), followed by an
Sponsor: Eureka Therapeutics Inc.
Check if you qualify for this liver cancer clinical trial in Portland, OR
If you're searching for liver cancer treatment options in Portland, OR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced liver cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.